Good Steward Wealth Advisors LLC Sells 966 Shares of Amgen Inc. $AMGN

Key Points

• Good Steward Wealth Advisors LLC has reduced its holdings in Amgen Inc. by 42.5%, selling 966 shares and ending the period with 1,305 shares valued at $364,000.
• Amgen reported earnings of $6.02 per share, exceeding estimates by $0.74, and achieved a revenue increase of 9.4% year over year.
• The company announced a quarterly dividend of $2.38 per share, resulting in an annualized dividend yield of 3.4%.

Good Steward Wealth Advisors LLC reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 42.5% in the second quarter, according to its most recent filing with the SEC. The fund owned 1,305 shares of the medical research company's stock after selling 966 shares during the period. Good Steward Wealth Advisors LLC's holdings in Amgen were worth $364,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Wealth Preservation Advisors LLC bought a new position in shares of Amgen in the first quarter worth approximately $25,000. First Pacific Financial lifted its position in Amgen by 304.5% during the first quarter. First Pacific Financial now owns 89 shares of the medical research company's stock valued at $28,000 after purchasing an additional 67 shares during the period. CBIZ Investment Advisory Services LLC lifted its position in Amgen by 1,214.3% during the first quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company's stock valued at $29,000 after purchasing an additional 85 shares during the period. Pinney & Scofield Inc. bought a new position in Amgen during the fourth quarter valued at approximately $26,000. Finally, Activest Wealth Management lifted its position in Amgen by 3,433.3% during the first quarter. Activest Wealth Management now owns 106 shares of the medical research company's stock valued at $33,000 after purchasing an additional 103 shares during the period. Hedge funds and other institutional investors own 76.50% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on AMGN shares. Cantor Fitzgerald reissued a "neutral" rating and issued a $305.00 price objective on shares of Amgen in a research note on Tuesday, June 24th. William Blair reissued an "outperform" rating on shares of Amgen in a research note on Tuesday, June 24th. Morgan Stanley increased their price objective on shares of Amgen from $330.00 to $333.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 6th. UBS Group reduced their price objective on shares of Amgen from $326.00 to $317.00 and set a "neutral" rating for the company in a research note on Wednesday, August 6th. Finally, Piper Sandler raised their target price on shares of Amgen from $328.00 to $342.00 and gave the company an "overweight" rating in a research note on Monday, August 25th. Seven investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Amgen has an average rating of "Hold" and an average target price of $304.43.

Amgen Price Performance

Shares of NASDAQ:AMGN traded up $1.12 on Thursday, reaching $275.83. The company's stock had a trading volume of 3,304,771 shares, compared to its average volume of 2,767,838. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $339.17. The company has a market cap of $148.50 billion, a P/E ratio of 22.55, a PEG ratio of 2.37 and a beta of 0.49. The company has a 50-day simple moving average of $291.25 and a 200 day simple moving average of $291.09. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.28 by $0.74. The firm had revenue of $9.18 billion during the quarter, compared to analyst estimates of $8.86 billion. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The business's revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the business earned $4.97 EPS. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. As a group, equities research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, September 12th. Stockholders of record on Friday, August 22nd were issued a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 3.5%. The ex-dividend date was Friday, August 22nd. Amgen's dividend payout ratio (DPR) is 77.84%.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,267 shares of the firm's stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the sale, the senior vice president owned 7,209 shares in the company, valued at approximately $2,141,000.91. This trade represents a 14.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.76% of the company's stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.